Clinical trial data now exit the research facility and enter the practice landscape at unprecedented speed and volume, and the arrival of COVID-19 has not slowed this rapid flow of information. In fact, the pandemic has shifted the release of data to even more accessible digital formats. At this point, clinicians who manage cancer and who hope to stay current and apply new research to their daily practice cannot do so on their own; they benefit from an expert’s interpretation and distillation of data as they carry new information from conference to bedside. The need for distilled information presented in an applicable format has risen faster than ever.

The heterogeneity seen in various tissue tumor types reveals a need for ever-more individualized approaches that targets molecular subtype, genetic mutations, and immunological profile for each patient. Our accredited tweetorial feed, with each program authored by international experts, provides a forum for interaction, communication, and education for all healthcare providers with an interest in cancer.